Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System - INFINITE-US

  • STATUS
    Recruiting
  • End date
    Mar 28, 2025
  • participants needed
    5
  • sponsor
    Intervene, Inc.
Send
Updated on 19 February 2024
See if I qualify

Summary

Prospective, non-randomized, multicenter pre-market early feasibility study (EFS) to evaluate subjects treated with the BlueLeaf System for the treatment of symptomatic CVI of the lower extremity

Description

The purpose of this early feasibility study is to provide information on the BlueLeaf System for the formation of one or more autogenous vein valves constructed from the vein wall of the femoral and/or popliteal vein, in subjects with CVI and who meet the specified eligibility criteria. In particular, the safety and technical feasibility of the procedure will be validated in patients in the United States, including the procedural steps, operator technique, and subject characteristics. The study will assess the safety and effectiveness of the study device acutely and through 5 years.

Details
Condition Chronic Venous Insufficiency (CVI), Deep Vein Reflux
Age 18years - 100years
Treatment BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)
Clinical Study IdentifierNCT04225806
SponsorIntervene, Inc.
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Failed at least 6 months of conservative therapy at some point during the course of their CVI management (symptoms not adequately resolved or patient non-compliant/unable to tolerate)
Deep system venous reflux characterized by >1 second reflux time in two contiguous vein segments (vein segments defined as: proximal femoral, distal femoral, and popliteal), as assessed by duplex ultrasound (DUS) with patient in the standing position
Presence of at least two potential target sites within a target vessel as assessed preliminarily by DUS, with a target site being defined as a segment within the femoral or popliteal vein that is
mm to 11mm in luminal diameter and at least 3cm long and absent features
that, in the Investigator's opinion, would preclude formation of a monocuspid
valve (at any orientation)
In the Investigator's opinion, the subject is a good candidate for treatment with the BlueLeaf System based on their symptoms, quality of life, anatomy, and the likelihood of benefit from continued conservative therapy

Exclusion Criteria

Untreated significant superficial venous incompetence which, in the opinion of the Investigator, may be the primary source of existing symptoms
Acute deep venous thrombosis (DVT) within 1 year of consent
Deep venous intervention (includes stenting) in the target limb or outflow vessels within 6 months of consent
Flow-limiting venous outflow obstruction central to the intended target sites, defined by a common femoral vein duplex exam found to have a continuous waveform without respiratory variation
Contraindications to all protocol specified anticoagulation options
Known and uncontrolled hypercoagulopathy (i.e. hypercoagulopathy that cannot be adequately managed/controlled with medication)
Women on long-term oral contraceptives
Non-ambulatory patients
Significant peripheral arterial disease with an ankle-brachial index of < 0.70 or with incompressible vessels
New York Heart Association Class III or IV heart failure
Patients with a history of right heart failure occurring as a consequence of, for example, biventricular failure, intrinsic pulmonary disease, chronic thromboembolic pulmonary hypertension, and other etiologies that result in elevated right-sided pressures
Active systemic infection
Invasive surgical procedure within the last 3 months that in the Investigator's opinion would interfere with the study procedure or results
Chronic renal insufficiency with creatinine level of 2mg/dL
Hemoglobin level < 9.0 mg/dL
Platelet count < 50,000 or > 1,000,000/mm3
Total white blood cell count < 3,000/mm3
Subject is enrolled in another clinical study that, in the opinion of the Investigator, may c
Comorbidity risks or other concerns which, in the opinion of the Investigator, either limits longevity or likelihood of complying with the protocol and its prescribed follow up (e.g. recent cancer or stroke); or precludes patient from being transitioned to open surgery if complication requiring surgical intervention occurs during the procedure (such as severe vein laceration)
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.